Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Int J Urol. 2014 Feb;21(2):164-8. doi: 10.1111/iju.12225. Epub 2013 Jul 30.
To examine the impact of tamsulosin on the rate of acute urinary retention following early catheter removal after robot-assisted laparoscopic radical prostatectomy.
A total of 236 patients who underwent robot-assisted laparoscopic radical prostatectomy for prostate cancer carried out by a single surgeon were enrolled in this randomized study. Patients were randomly divided into two groups: treatment with tamsulosin (0.4 mg) from 1 day before to 14 days after surgery (tamsulosin group), or no tamsulosin treatment (control group). The urethral catheter was removed on the fifth postoperative day. The primary end-point was the acute urinary retention rate. Changes in each domain of the International Continence Society male short-form questionnaire and uroflowmetry parameters were secondary end-points.
The primary end-point was assessed in 218 patients (92.4%; n = 109 in each group). It was not assessed in 18 patients because of cystographic leak from the vesicourethral anastomosis. The acute urinary retention rate was lower in the tamsulosin group (7.3%) than in the control group (17.4%, P = 0.018). Multivariate logistic regression analysis identified tamsulosin treatment and the operative experience of the surgeon as independent risk factors for acute urinary retention. Tamsulosin-treated patients had a 0.30-fold lower risk of developing acute urinary retention compared with control patients (95% confidence interval 0.12-0.76; P = 0.011). None of the International Continence Society male questionnaire domain scores showed significant changes between the groups.
Perioperative treatment with tamsulosin in patients undergoing robot-assisted laparoscopic radical prostatectomy reduces the rate of acute urinary retention after early catheter removal, without aggravating urinary incontinence.
探讨坦索罗辛对机器人辅助腹腔镜前列腺根治术后早期拔除尿管后急性尿潴留发生率的影响。
本随机研究纳入了 236 例由同一位外科医生行机器人辅助腹腔镜前列腺根治术的前列腺癌患者。患者被随机分为两组:术后 1 天至 14 天使用坦索罗辛(0.4mg)治疗(坦索罗辛组),或不使用坦索罗辛治疗(对照组)。术后第 5 天行尿道尿管拔除。主要终点是急性尿潴留发生率。次要终点为国际尿控协会男性短问卷各领域的变化和尿流率参数。
218 例患者(92.4%;每组 109 例)评估了主要终点,18 例患者因尿道膀胱吻合口漏尿而未评估。坦索罗辛组(7.3%)的急性尿潴留发生率低于对照组(17.4%,P=0.018)。多变量逻辑回归分析确定坦索罗辛治疗和外科医生的手术经验是急性尿潴留的独立危险因素。与对照组相比,坦索罗辛治疗组发生急性尿潴留的风险降低 0.30 倍(95%置信区间 0.12-0.76;P=0.011)。两组间国际尿控协会男性问卷各领域评分均无显著变化。
在机器人辅助腹腔镜前列腺根治术后的患者中,围手术期使用坦索罗辛可降低早期尿管拔除后急性尿潴留的发生率,且不会加重尿失禁。